Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2581-3140
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees96
Next Earnings DateN/A
OptionableNot Optionable
BRAINSWAY LTD/S (NASDAQ:BWAY) Frequently Asked Questions
What is BRAINSWAY LTD/S's stock symbol?
BRAINSWAY LTD/S trades on the NASDAQ under the ticker symbol "BWAY."
How were BRAINSWAY LTD/S's earnings last quarter?
BRAINSWAY LTD/S (NASDAQ:BWAY) announced its quarterly earnings data on Monday, November, 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The firm had revenue of $5.93 million for the quarter, compared to analyst estimates of $5.75 million. View BRAINSWAY LTD/S's Earnings History.
What price target have analysts set for BWAY?
5 analysts have issued twelve-month target prices for BRAINSWAY LTD/S's shares. Their forecasts range from $13.00 to $19.00. On average, they expect BRAINSWAY LTD/S's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price. View Analyst Price Targets for BRAINSWAY LTD/S.
What is the consensus analysts' recommendation for BRAINSWAY LTD/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BRAINSWAY LTD/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BRAINSWAY LTD/S.
Has BRAINSWAY LTD/S been receiving favorable news coverage?
Headlines about BWAY stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BRAINSWAY LTD/S earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for BRAINSWAY LTD/S.
Who are some of BRAINSWAY LTD/S's key competitors?
Some companies that are related to BRAINSWAY LTD/S include SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Restoration Robotics (HAIR), SeaSpine (SPNE), Iradimed (IRMD), Accuray (ARAY), Repro-Med Systems (REPR), Repro Med Systems (KRMD), Westaim (WEDXF) and Apyx Medical (APYX).
What other stocks do shareholders of BRAINSWAY LTD/S own?
Who are BRAINSWAY LTD/S's key executives?
BRAINSWAY LTD/S's management team includes the folowing people:
- Dr. David Zacut, Founder & Chairman (Age 66)
- Prof. Abraham Zangen, Founder & Member of the Scientific Advisory Board (Age 49)
- Dr. Yiftach Roth, Founder & Chief Scientist (Age 48)
- Mr. Hadar Levy, Chief Financial Officer (Age 45)
- Mr. Ronen Segal, Chief Technology Officer (Age 46)
When did BRAINSWAY LTD/S IPO?
(BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor served as the underwriter for the IPO.
Who are BRAINSWAY LTD/S's major shareholders?
BRAINSWAY LTD/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Raymond James & Associates (0.26%) and Victory Capital Management Inc. (0.11%).
Which major investors are selling BRAINSWAY LTD/S stock?
BWAY stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc..
Which major investors are buying BRAINSWAY LTD/S stock?
BWAY stock was acquired by a variety of institutional investors in the last quarter, including Raymond James & Associates.
How do I buy shares of BRAINSWAY LTD/S?
Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BRAINSWAY LTD/S's stock price today?
One share of BWAY stock can currently be purchased for approximately $12.00.
How big of a company is BRAINSWAY LTD/S?
What is BRAINSWAY LTD/S's official website?
How can I contact BRAINSWAY LTD/S?
BRAINSWAY LTD/S's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL, Jerusalem L3, 91451. The company can be reached via phone at 972-2581-3140 or via email at [email protected]
MarketBeat Community Rating for BRAINSWAY LTD/S (NASDAQ BWAY)
MarketBeat's community ratings are surveys of what our community members think about BRAINSWAY LTD/S and other stocks. Vote "Outperform" if you believe BWAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BWAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
